Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genasense (Genta Inc).

D Banerjee1

  • 1Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. banerjee@aol.com

Current Opinion in Investigational Drugs (London, England : 2000)
|September 22, 2001
PubMed
Summary
This summary is machine-generated.

Genasense, an antisense oligonucleotide targeting Bcl-2, is in late-stage trials for various cancers. This innovative therapy aims to improve treatment outcomes for patients with melanoma and other malignancies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Yttrium-88 glass microsphere: A potential radiotracer for radioactive particle tracking applications.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2026
Same author

Does active case finding detect TB early in programme settings? A national-level study in India.

Public health action·2026
Same author

Axisymmetric Eigenmodes Excited by Alpha Particle Energy Gradients in JET D-T Plasmas.

Physical review letters·2026
Same author

Insights into the Chemical Durability and Structure of ZnO-Incorporated Sodium Borosilicate Glasses from Solid-State NMR.

The journal of physical chemistry. B·2025
Same author

Neutrophil-lymphocyte ratio as an early predictive biomarker for severity in patients with high altitude pulmonary edema.

Medical journal, Armed Forces India·2025
Same author

Fabry disease in the haemodialysis population: outcome of a UK screening study (SoFAH).

BMC nephrology·2025
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Genasense (G-3139) is an antisense oligonucleotide targeting Bcl-2.
  • It is developed by Genta for intravenous infusion in cancer treatment.
  • Bcl-2 plays a crucial role in cancer cell survival.

Purpose of the Study:

  • To evaluate Genasense as a potential treatment for various cancers.
  • To assess its efficacy in phase III clinical trials for malignant melanoma, chronic lymphocytic leukemia (CLL), and acute myelocytic leukemia (AML).
  • To investigate its potential in improving response rates, duration, and quality of life in multiple myeloma patients.

Main Methods:

  • Genasense is administered as an intravenous drip infusion.
  • Phase III clinical trials are ongoing for malignant melanoma, CLL, AML, and multiple myeloma.

Related Experiment Videos

  • Patents have been secured for Genasense composition, analogs, and novel backbone structures enhancing antisense affinity.

    • Main Results:

    • Genasense has received Fast Track and Orphan Drug status for malignant melanoma.
    • Pivotal phase III trials in melanoma, CLL, and AML were initiated by 2001.
    • Anticipated launch in 2002 pending positive trial results.

    Conclusions:

    • Genasense shows promise as a novel therapeutic agent for various cancers.
    • Ongoing clinical trials are critical for its potential market approval and patient access.
    • Strategic licensing and patent protection position Genta favorably for Genasense commercialization.